Company Overview of LFB S.A.
LFB S.A., a biopharmaceutical company, develops, manufactures, and markets medicinal products for the treatment of serious and rare diseases in the therapeutic areas of immunology, haemostasis, and intensive care worldwide. Its products include plasma-derived, recombinant, and cell therapy medicinal products. The company offers therapeutic solutions to treat primary immuno-deficiency, autoimmune diseases, and acquired troubles, such as secondary immuno-deficiency; and constitutional bleeding disorders, as well as biomedicines to treat patients who are often in a critical condition due to severe deficiencies in essential plasma proteins. It is also involved in the services and intermediate bi...
3, Avenue des Tropiques
Les Ulis, 91958
Founded in 1994
33 1 69 82 70 10
33 1 69 07 19 03
Key Executives for LFB S.A.
Chairman, Chief Executive Officer, Chairman of LFB Biotechnologies and Chief Executive Officer of LFB Biomedicaments
Executive Vice-President of Finance & Strategy
Chief Executive Officer of LFB Hemoderivados E Biotecnologia Ltda, Brazil
Sales Director and Executive Vice-President of Global Marketing & Sales - Lfb Biomedicaments Sa
Managing Director of Europlasma AT GmbH
Compensation as of Fiscal Year 2016.
LFB S.A. Key Developments
LFB S.A. Reports Consolidated Earnings Results for 2015
Apr 18 16
LFB S.A. reported consolidated earnings results for 2015. The company reported turnover of EUR 502.4 million, operational earnings of EUR 12 million, net earnings of EUR 0.3 million against turnover of EUR 501.9 million, operational earnings of EUR 25.2 million, net earnings of EUR 13 million a year ago.
LFB S.A. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016
Mar 11 16
LFB S.A. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016 . Venue: Grand Hyatt, Tokyo, Japan.
Knight Therapeutics Inc. and LFB S.A. Announce Filing Of New Drug Submission for Atryn(r)
Aug 6 15
Knight Therapeutics Inc. and LFB S.A. announced that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for ATryn(r) [Antithrombin (Recombinant)] for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries